AP NEWS

Global Autoimmune Drugs Market 2018-2022 | Market Dominance by TNF- α Inhibitors to Boost Growth | Technavio

December 26, 2018

LONDON--(BUSINESS WIRE)--Dec 26, 2018--The global autoimmune drugs market is expected to post a CAGR of over 8% during the period 2018-2022, according to the latest market research report by .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181226005054/en/

Technavio has published a new market research report on the global autoimmune drugs market from 2018-2022. (Graphic: Business Wire)

A key factor driving the growth of the global autoimmune drugs market is the introduction of affordable biosimilars. Biosimilars have emerged as a replacement for biologics that are expensive and unaffordable for most patients. The lower price of biosimilars is attracting healthcare providers to offer reimbursement for them. Thus, the introduction of biosimilars has increased access to an advanced treatment option for patients with autoimmune disorders.

This market research report on the also provides an analysis of the most important trends expected to impact the market outlook during the forecast period.

This report is available at a USD 1,000 discount for a limited time only:

Global autoimmune drugs market: Market dominance by TNF-α inhibitors

The global autoimmune drugs market is dominated by TNF-α inhibitors that are very effective as they target specific receptors on the cell surface. HUMIRA, Enbrel, Cimzia, and SIMPONI are some of the widely sold TNF-α inhibitors. These inhibitors are routinely prescribed as the first line of treatment for the management of autoimmune disorders mainly psoriasis, rheumatoid arthritis, and multiple sclerosis.

Several efforts are being made to introduce a different class of drugs for autoimmune diseases. Some of the emerging drugs include the JAK kinase inhibitors that are targeting the JAK kinase protein, a mechanism distinct from those of TNF-α inhibitors.

“A major segment of the autoimmune drugs is occupied by the biologics most of which have faced or are on the verge of facing patent expiry across different economies in the world. These trends are welcoming biosimilar versions of these biologics into the market, many of which are already available in the market,” says a senior analyst at Technavio.

Global autoimmune drugs market: Segmentation analysis

This market research report segments the global autoimmune drugs market by therapy area (rheumatoid arthritis, multiple sclerosis, psoriasis, and inflammatory bowel disease) and geographical regions (APAC, EMEA, and the Americas).

The Americas region led the market in 2017 with a market share of over 54%, followed by EMEA and APAC respectively. Although the EMEA region held a market share less than the Americas in 2017, it is expected to register the highest incremental growth during the forecast period.

Looking for more information on this market?

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

Market ecosystem Market characteristics Market segmentation analysis

Market Sizing

Market definition Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

Regional comparison Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Vendors covered Vendor classification Market positioning of vendors Competitive scenario

About Technavio

is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at .

View source version on businesswire.com:https://www.businesswire.com/news/home/20181226005054/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Technavio Research

Copyright Business Wire 2018.

PUB: 12/26/2018 09:20 AM/DISC: 12/26/2018 09:20 AM

http://www.businesswire.com/news/home/20181226005054/en

AP RADIO
Update hourly